The nonreceptor tyrosine kinases of the Src family (SFK) are frequently deregulated in human colorectal cancer (CRC), and they have been implicated in tumour growth and metastasis. How SFK are activated in this cancer has not been clearly established. Here, we show that the SFK-dependent invasion is induced by inactivation of the negative regulator C-terminal Src kinase, Csk. While the level of Csk was inconsistent with SFK activity in colon cancer cells, its membrane translocation, needed for efficient regulation of membrane-localized SFK activity, was impaired. Accordingly, Csk downregulation did not affect SFK oncogenic activity in these cells, whereas expression of a membrane-localized form of this kinase affected their invasive activity. Downregulation of the transmembrane and rafts-localized Csk-binding protein/ phosphoprotein associated with glycosphingolipid-enriched microdomain (PAG), was instrumental for the cytoplasmic accumulation of Csk. Re-expression of PAG in cells from late-stage CRC inhibited SFK invasive activity in a Cskdependent manner. Conversely, inactivation of its residual expression in early-stage CRC cells promoted SFK invasive activity. Finally, this mechanism was specific to CRC as Csk coupling to SFK was readily detected in breast cancer cells. Therefore, Csk mis-localization defines a novel mechanism for SFK oncogenic activation in CRC cells.
Introduction
The nonreceptor tyrosine kinases of the Src family (SFK) have important roles in cell growth and migration induced by extracellular stimuli, including growth factors and integrins (Thomas and Brugge, 1997) . They also show oncogenic activity when deregulated, a situation originally found with v-Src, the transforming product of the avian retrovirus Rous sarcoma virus (Yeatman, 2004) . Since then, SFK have been reported as deregulated in a large variety of human cancers (Summy and Gallick, 2003) . Remarkably, kinase activities of Src and Yes are frequently elevated in colorectal cancer (CRC), as compared with the normal counterpart, and this has been associated with a poor clinical outcome (Summy and Gallick, 2003) . Since then, they have been implicated in colon tumour progression and metastasis (Summy and Gallick, 2003) . For example, Src regulates growth, survival and invasion of CRC cells in vitro (Summy and Gallick, 2003; Emaduddin et al., 2008) and contributes to tumour growth, angiogenesis and metastasis in mouse xenografts (Summy and Gallick, 2003) . The function of Yes in CRC is less clear, although a role in cellular invasion has been proposed for this protein (Summy and Gallick, 2003) . On the basis of these observations, SFK have become attractive therapeutic targets in advanced CRC, and several small inhibitors are under clinical trials.
How SFK are deregulated in colon cancer is an important issue that has not been thoroughly addressed. In contrast to Ras, Src activation by mutation is a rare event, suggesting the existence of alternative mechanisms for oncogenesis (Irby et al., 1999) . Kinase activation often correlates with protein overexpression (Yeatman, 2004) , but overexpression alone in a normal cellular context is not sufficient to induce cell transformation, as SFK are subjected to strict regulation that maintain the enzymes in an inactive form. Precisely, this relies on intramolecular interactions of the SH2 domain with pTyr529 (referring to human Src) and the SH3 domain within a linker domain between the SH2 and the catalytic core, thus keeping the kinase in a closed and inactive conformation (Boggon and Eck, 2004) . Phosphorylation of Tyr529 is therefore crucial for Src inactivation. Accordingly, mutation of this residue into Phe leads to oncogenic activity and deletion of this residue is observed in all retroviral SFK alleles, which largely contributes to their transforming activity. As SFK mutation is highly infrequent in human cancer, it has been postulated that oncogenic activation implicates the alteration of SFK regulators, all of which have yet to be identified (Yeatman, 2004) . In this context, several candidates have been suggested to disrupt the SH2-pTyr529 intramolecular interaction. These include growth factor receptors, through their association with SFK-SH2 (Mao et al., 1997) , and tyrosine phosphatases that dephosphorylate pTyr529 (Liang et al., 2007; Zhu et al., 2007; Zheng et al., 2008) . Although probably activated in a subset of tumours, they may not account for the kinase deregulation observed in CRC.
An additional possible mechanism for deregulation of SFK activity involves the functional alteration of the kinase activity responsible for Tyr529 phosphorylation, the cytoplasmic tyrosine kinase, C-terminal Src kinase (Csk). The potential importance of this mechanism has been highlighted by the phenotypic consequences of Csk gene inactivation in mice, leading to aberrant SFK activity and lethality during embryogenesis (Imamoto and Soriano, 1993; Nada et al., 1993) . Similarly, loss of dCsk in Drosophila can lead to overproliferation and disorganization of tissue architecture (Stewart et al., 2003; Read et al., 2004) . Nevertheless, the involvement of Csk in CRC remains controversial. Indeed, Csk level was found either downregulated or upregulated in CRC tumours (Be´nistant et al., 2001; Cam et al., 2001; Zhu et al., 2008) , inconsistent with a potential tumour suppressor function. This notion is reinforced by the detection of Csk autoantibodies in some patients with CRC, indicating that this tyrosine kinase is a novel tumour antigen in this cancer (Be´nistant et al., 2001) . Interestingly, Although SFK are very good substrates in vitro, they do not interact efficiently with Csk in vivo. This is because of the fact that while SFK are present at the membranes, inactive Csk is strictly cytosolic. Thus, in vivo activity additionally requires membrane-associated Csk-binders that allow its recruitment to subcellular compartments in which the SFK reside. For example, the cytoskeletal-associated protein, paxillin, recruits Csk to the focal adhesion sites for the regulation of cell migration (Schaller and Parsons, 1995) , whereas the signalling protein, Dok-1, induces Csk translocation to the plasma membrane for mitogenic regulation (Zhao et al., 2006) . Additional Csk-binders have been identified, including the structural protein of caveolae, caveolin-1 (Lee et al., 2000) , the junctional proteins VE-cadherin (Baumeister et al., 2005) and ZO-1 and the transmembrane protein phosphoprotein associated with glycosphingolipidenriched microdomain (PAG)/Csk-binding protein (Cbp) (Brdicka et al., 2000; Kawabuchi et al., 2000) localized in cholesterol-enriched membrane domains or rafts (named PAG in this study). Interestingly, SFK phosphorylation of these proteins triggers their binding to Csk through a SH2-pTyr-dependent mechanism, which creates a negative feedback regulatory loop. Yet, the status of these proteins in CRC is largely unknown. Here, we show that Csk mis-localization defines an important and novel mechanism for SFK oncogenic activation in CRC. Moreover, we have identified the PAG transmembrane protein as one of Cbp involved in this molecular process, resulting in the induction of SFK invasive activity.
Results

Csk membrane localization is reduced in CRC cells
We first analyzed Csk activity in CRC cells. As shown in Figure 1a (left panel), Csk level was higher in cell lines from CRC metastases (SW620 and Colo205) as compared with those that originated from primary tumours (SW480, HCT116 and HT29). Moreover, Csk levels positively correlated with Src activity, in agreement with the situation observed in CRC tumour biopsies (Be´ni-stant et al., 2001) . In contrast, Csk levels inversely correlated with SFK activities in breast cancer cells of various sub-types (Oestrogen receptor (ER) þ , HER2 þ , and triple negative for ER, progesterone receptor and HER2) (Figure 1a , right panel), suggesting that Csk is 
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A Sirvent et al still coupled to SFK activities in this cancer. We thus hypothesized that Csk could be inactive in colorectal tumours, and we analyzed Csk catalytic activity in CRC cells. To this end, Csk was immunoprecipitated from cancer cell lysates, and its in vitro kinase activity was measured using poly-Glu-Tyr as a substrate. A higher kinase activity was obtained from CRC cell lines from more advanced aggressive cancer, which tightly correlated with its expression level (Figure 1b) . Indeed, specific activities were of 0.7-1.4 range, indicating that Csk was not significantly altered in CRC cells. Similar results were obtained using the kinase inactive FynK298M as a specific substrate (Koegl et al., 1994) (specific activity of 0.9-1.15 range), indicating that its substrate specificity was not modified either. We next measured Csk sub-cellular localization by cell fractionation ( Figure 1c, left panel) . Surprisingly, Csk was predominantly found in cytosolic fractions, unlike SFK, which were largely localized at the membranes. In contrast, Csk was equally partitioned in membranes and cytosolic fractions of breast cancer cells ( Figure 1c , right panels), indicating that its membrane localization was specifically impaired in CRC cells.
Csk inhibition does not affect SFK oncogenic activity in CRC cells
The function of Csk was next addressed in CRC cells. We first confirmed that the Csk substrates SFK have important roles in transforming properties of CRC cells; specifically, anchorage-independent growth and invasion were inhibited by treatment with the SFK pharmacological inhibitor, SU6656 (Figure 2a) . Similar results were obtained in MCF7 and ZR75.1 ER þ breast cancer cells (Figure 2a ), which is in agreement with an important role for SFK in ER oncogenic signalling (Ishizawar et al., 2004; Sirvent et al., 2007) . In contrast, the SFK inhibitor had no effect on HER2 þ breast cancer cells, SKBR3 and BT474, indicating that SFK do not have a role in every breast cancer cell ( (Sirvent et al., 2007) and not shown). Owing to the important function of SFK in CRC cells, we next investigated the role of Csk in the growth and invasion of CRC cells. To this end, Csk was inactivated using a small hairpin RNA (shRNA) approach that induces a >70 % reduction of its protein level (Figure 2b (Figure 2c ), indicating that Csk is active in ER þ breast cancer cells. We next confirmed this data with a pharmacological approach using the small molecule Csk inhibitor, ASN2324598 (Kunte et al., 2005) . This compound reduced the capacity of Csk to phosphorylate SFK both in an enzymatic assay and in cells, as illustrated with the example of MCF7-treated cells (Supplementary Figure 2) . At the functional level, ASN2324598 significantly increased both anchorage-independent growth and invasion of MCF7 cells, while having no effect on Colo205 cells (Supplementary Figure 2) . We therefore concluded that Csk is essentially uncoupled from SFK activities in CRC cells, in contrast to breast cancer cells.
A membrane-localized Csk re-regulates SFK invasive activity in CRC cells We next asked whether Csk inhibition could be due to membrane mis-localization. To address this question, Csk was fused to the Fyn (1-63) with both a myristoylation and palmitoylation site (palm-Csk). Unlike wild-type Csk, this sequence allows Csk protein membrane targeting, more specifically in cholesterolenriched or raft domains, in which a pool of SFK reside (Resh, 1999) (Figure 3a) . As a consequence, palm-Csk reduced SFK activities of SW620 cells by about 50%, unlike Csk (Figure 3b ). This data was next confirmed by confocal immunofluorescence microscopy. Figure 3e shows predominant cytoplasmic Csk localization, both at the overexpressed and the endogenous protein level. Some membrane staining could be detected in wild-type Csk overexpressing cells, which, however, does not affect SFK activities. In contrast, cells expressing palmCsk show strong Csk membrane localization, leading to significant decrease in SFK activities in agreement with biochemical results. The effect of rafts-localized Csk was next assessed on SFK oncogenic signalling. We found that, unlike Csk, palm-Csk strongly inhibited cellular invasiveness (Figure 3d) . However, the palm-Csk fusion protein did not affect cell growth (Figure 3c ), indicating that the pool of SFK thus targeted was not involved in proliferation. We concluded that the Csk targeting to the membrane is sufficient to allow regulation of SFK invasive activity in CRC cells. Surprisingly, expression of wild-type Csk significantly increased the growth of SW620 cells in soft agar conditions (Figure 3c ). The reason for this is currently unknown, but it suggests that Csk could have a positive function, perhaps independent of SFK in some circumstances to be identified.
Csk uncoupling is associated with downregulation of PAG in CRC We next searched for Cbps involved in uncoupling of Csk. As palm-Csk was concentrated in lipid rafts (Figure 3a) , we hypothesized that the transmembrane was strongly reduced in most neoplastic tissues examined (8 of 10) (Figure 4b ). PAG inhibition was also confirmed at the protein level using immunofluorescent staining from normal and transformed colorectal tissues. PAG-specific immunostaining was reduced in these tumour tissues, unlike that of Csk (Figure 4c) . Similar results were obtained with an antibody specific to the PAG C-terminus, confirming the specificity of PAG downregulation (not shown). We thus concluded that PAG expression is inhibited in CRC. We next analyzed the biological consequence of PAG downregulation. First, we reintroduced PAG in cells derived from advanced CRC harbouring a low to undetectable level of endogenous PAG protein. We found that de novo expression of this transmembrane protein significantly increased Csk membrane localization and reduced SFK activities (Figures 3e, 5a and b) . At the functional level, PAG mimicked the effects of palm-Csk, that is, a reduction of cell invasiveness, with no effect on soft agar cell growth (Figure 5c ). Whether this PAG activity was mediated by Csk was next addressed. We found that PAG-regulated effects were counteracted by Csk inhibition. Specifically, treatment of PAG-expressing cells with ASN2324598 or transduction of shRNAs that specifically target Csk largely restored SFK kinase activity (Figures 5d and e) and cell invasion (Figure 5f ). Lastly, residual PAG expression was knocked down in cells derived from early CRC using a shRNA strategy (Figure 6a ). We found that its inactivation induced a significant decrease in Csk membrane localization (Figure 6b ) and a remarkable increase in SFK activities (Figure 6a and Supplementary  Figure 3) . Again, although PAG downregulation did not affect anchorage-independent growth of these cells (Figure 6c) , it strongly increased their cellular invasiveness (Figure 6d ). Similar results were obtained with a distinct shRNA sequence that also targets PAG (Supplementary Figure 3) . Finally, we also observed that this increased cellular response was neutralized by the SFK inhibitor, SU6656 (Figure 6d ). Therefore, we concluded that PAG is implicated in Csk inactivation controlling SFK invasive activity of CRC cells.
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Discussion
Although SFK have been largely implicated in CRC, the source of their oncogenic activity in this cancer is only partially understood. Here, we bring novel insights into the mechanisms involved. Although protein overexpression clearly provides part of the response (Yeatman, 2004) , additional mechanisms are expected to de-repress their catalytic activity. Accordingly, we show that mislocalization of the negative regulator, Csk, is one of the important means for increased invasion of cancer cells through deregulated SFK activity. Indeed, Csk inactivation renders SFK overexpression sufficient to induce a deregulated form of the kinase with oncogenic properties. This mechanism may particularly operate in advanced CRC cells, in which tumour cells harbour maximal Csk membrane delocalization together with a high SFK level. In this respect, a moderate expression of wild-type Src in advanced CRC SW620 cells is sufficient to increase oncogenic properties, in particular, the proinvasive activity (Leroy et al., 2009 ). This may explain why CRC cells can withstand high Csk levels, as observed in tumour biopsies. Whether this mechanism is specific to CRC is currently not known, but our data indicate that it may not operate in breast cancer, in which Csk was still coupled to SFK. Alternative strategies may thus be used by these cells to overcome Csk-mediated inhibition, including SFK-increased protein stabilization (Tan et al., 2005) and the interaction with growth factor or hormonal receptors. It will, however, be important to address whether a similar mechanism operates in additional cancers in which SFK are found to be deregulated.
A second feature of SFK oncogenic activity arising from our results is the existence of distinct pools of SFK controlling various aspects of cellular transformation. This notion is emphasized by the fact that rafts-targeted Csk re-regulates SFK invasive activity without affecting its growth-promoting function. Moreover, Csk relocalization to these membranes induced, at most, a 50% reduction of SFK activity, confirming that it does not target all pools of SFK present in these cells. Accordingly, spatial regulation has been considered as an important feature of signal specificity induced by SFK in nontransformed cells (Veracini et al., 2006 (Veracini et al., , 2008 , and this may apply for transformed cells as well. For example, when localized at focal adhesions, SFK has important roles in cell growth and survival (Frame, 2004) . This pool of SFK may not be regulated by a membrane-localized Csk, but rather by a fraction of Csk present at focal adhesion in complex with paxillin or Fak. An important issue related to this notion is the nature of the pool of SFK targeted by palm-Csk. As this fusion protein is concentrated in lipid rafts, we believe that it targets the pool of SFK present in these domains. Lipid rafts have been proposed to be important regulators of SFK-transforming activity (Collin et al., 2007; Oneyama et al., 2008) . Nevertheless, their roles in CRC cells are ill-defined. A function has been assigned to them for the regulation of cell-cell adhesion, including adherent and tight junctions, in epithelial cells (Nusrat et al., 2000; Causeret et al., 2005) . Therefore, Csk inhibition may increase the effects of SFK oncogenic activity on cell dissociation and migration, processes involved in the epithelial to mesenchymal transition, and required for cell dissemination and metastasis (Frame, 2004) . However, SFK also control invasion of advanced CRC cells, such as SW620, that have lost adherent junctions, and this process is still inhibited when targeting Csk to the lipid rafts. Therefore, a yet to be identified, additional pool of SFK present in lipid rafts may promote cellular invasion.
We have also identified PAG downregulation as an important mechanism of Csk inactivation in CRC cells. PAG belongs to the family of transmembrane adaptor proteins, the founder being the linker of activation of T cells (LAT), and it is ubiquitously expressed, unlike other members of the transmembrane adaptor protein family (Horejsi et al., 2004) . PAG was originally identified as a Csk-binder, implicating phosphorylation of Tyr317 on PAG, but it contains eight additional SFK phosphorylation sites, allowing interaction with SH2-containing proteins, two poly-Pro motifs for interaction with SH3-containing proteins and two palmitoylation sites implicated in lipid rafts localization (Horejsi et al., 2004) . Known interactors include the E3-ligase SOCS1 (Ingley et al., 2006) , the negative Ras regulator RasGAP (Smida et al., 2007) and SFK themselves Solheim et al., 2008; Tauzin et al., 2008) . Besides, we recently reported an unanticipated interaction between PAG N-terminus and the Neu-3 sialidase (Veracini et al., 2008) , controlling lipid raft properties (Miyagi et al., 2008) . This data would predict that PAG could have diverse functions during oncogenesis. Accordingly, a negative function has been recently reported in CRC tumour growth after xenotransplantation into immunodeficient mouse , but the underlying mechanism has not been addressed. Moreover, by sequestering SFK in lipid rafts, PAG inhibits Src-transforming activity in mouse fibroblasts , but promotes Lyn oncogenic activity in B lymphoma (Tauzin et al., 2008) . In both cases, PAG effects were independent of Csk. In contrast, our data clearly indicate that PAGnegative function implicates Csk activity in CRC cells, which is more relevant to colon cancer cell biology, as the previous studies used Csk À/À mouse embryonic fibroblasts as their model for cell transformation. An additional difference may rely on the high level of expressed PAG in fibroblasts that forces the segregation of Src in rafts, a situation that was not observed in CRC cells (see Figure 4a) . Nevertheless, our study does not exclude additional Csk-independent function of PAG in CRC cells. How PAG is inactivated in CRC is another important issue that was partially addressed in this report. PAG expression is frequently inhibited in CRC (Oneyama et al., 2008 and this report) , confirming the importance of this mechanism for SFK deregulation. Nevertheless, PAG is present in cells of early CRC, surmising additional mechanisms for signalling inhibition. Accordingly, one mechanism might implicate tyrosine phosphatases that dephosphorylate Csk-binding sites, as reported with SHP2 during growth factor receptor signalling in nontransformed cells .
Finally, our results may have significant implications in oncogenesis and cancer therapy. They first indicate that inhibition of a Cbp can be an important means to activation of SFK oncogenic signalling. In this respect, it will be important to analyze the role of additional Cbps in CRC. It also uncovers a novel strategy used by cancer cells to induce oncogenic activity of a protooncogene in the absence of a genetic mechanism, implicating a mis-localization of its negative regulators. Although not experimentally verified, this could also apply to signalling proteins such as small GTPases of the Ras or Rho family. Finally, as several small SFK inhibitors are under clinical trials in human cancer, several of them may affect Csk activity as well, thus lowering their efficacy towards SFK in tumourigenic tissues. Although our data predict that this may not affect their activity in CRC, in which Csk is inactive, it will be essential to determine their effects on Csk activity in other cancers, such as breast cancer. Finally, although very active in vitro, these inhibitors may not target all pools of SFK, including the ones present in lipid rafts, owing to the lipophilic microenvironment. It will, therefore, be important to design inhibitors that will also target this pool of SFK in advanced CRC tumours.
Materials and methods
Reagents SU6656 was purchased from Calbiochem (La Jolla, CA, USA) and ASN2324598 from Asinex (Moscow, Russia). [g 32 P]ATP was purchased from Amersham, poly-Glu-Tyr and Enolase from Sigma Aldrich (St Quentin, France). Purified FynK298M (FynK À ) was described in Koegl et al. (1994) . Anti-SFK (cst1) was described in Veracini et al. (2006) ; anti-Src specific (2.17) antibody was a generous gift from Dr S Parsons (University of Virginia, VA, USA). Anti-Csk was described in Be´nistant et al. (2001) , anti-PAG in Veracini et al. (2008) and anti-Cbp in Oneyama et al. (2008) . Polyclonal anti-Src [pY 418 ] and anti-Src [pY 530 ]-specific antibodies were obtained from Biosource (Invitrogen, Cergy-pontoise, France), anti-flotillin-1 and anti-pan-caveolin from BD BioScience (Le pont de Claix, France) and anti-transferrin receptor from Zymed (San Francisco, CA, USA). Alexa Fluor 488 dye-conjugated goat anti-mouse or goat anti-rabbit and Alexa Fluor 594 dye-conjugated goat anti-mouse or goat anti-rabbit were from Molecular Probes (Biosource, Invitrogen). Antiphosphotyrosine 4G10 and anti-a-tubulin were a gift from P Mangeat and N Morin, respectively (CRBM, Montpellier, France). Csk (Veracini et al., 2008), palm-Csk (Fyn[1-63] -Csk) have been cloned into pBABE retroviral vector. pRETRO-SUPER-expressing shRNAs, Csk 1562 (shRNA Csk 1) and Csk 340 (shRNA Csk 2), were from TRANSAT (Saint-Priest, France). A pRETRO-SUPER universal scramble with the (Clontech) . A construct expressing a shRNA Luc directed against the unrelated human luciferase was used as a negative control (Clontech). peFBOS encoding human PAG (Veracini et al., 2008) has been subcloned into pBABE retroviral vector.
Cell culture and retroviral infections
Cell lines (ATCC, Rockville, MD) were cultured, as described previously (Sirvent et al., 2007) , in specific growth medium (Invitrogen) supplemented with 10% fetal calf serum: RPMI for SW620, SW480, HCT116, HT29, Colo205 and MCF7; Dulbecco's modified Eagle's media-F-12 for MDAMB231, MDAMB468, ZR75.1 and SKBR3. For drug treatments, cells were treated with the indicated inhibitor (or dimethyl sulfoxide as a vehicle) for 24 h, as indicated, in growth medium supplemented with 1% fetal calf serum. Retroviral infections were performed as in Sirvent et al. (2007) and stable cell lines have been obtained in a polyclonal background by puromycin (1 mg/ml) selection.
Anchorage-independent cell growth, migration and invasion assays For anchorage-independent cell growth, 0.67% agar in medium was layered on the bottom of a 12-well plate, and 1000 (CRC cells) or 4000 (MCF7 and ZR75.1) cells per well were seeded on the top of this layer in a 0.33% agar medium. After 18-21 days, colonies having >50 cells were scored positive. Inhibitors or vehicle (dimethyl sulfoxide) were added at every 3 days. Cell invasion assays were performed in Boyden chambers (BD Bioscience) using 50 000 (CRC) and 150 000 (MCF7 and ZR75.1) cells for, respectively, 24 h or 48 h, and in the presence of 100 ml of Matrigel (1.5 mg/ml) (BD Bioscience).
Human tissues collection, immunofluorescent staining, microdissection and quantitative PCR analysis Specimens of colon tumours (10 patients) and histologically normal epithelium were obtained from the pathologist according to governmental local ethic committee regulations (CHU Care´meau, Nıˆmes, France). Tissue sections, microdissection and RNA preparation were performed as previously described (Pannequin et al., 2007) . Immunofluorescent staining was done as in Pannequin et al. (2007) using 1/50 (PAG) to 1/200 (Csk) dilutions of previously described antibodies. Real-time quantitative PCR analyses were performed using the LightCycler Technology (Roche Diagnostic, Meylan, France), as previously described (Boureux et al., 2005) . Transcript levels were normalized to 36B4 mRNA levels. Primers used were as follows: PAG forward 5 0 -CAGTGGATACCATGCTCACG-3 0 and reverse 5 0 -AGATTTTGCCTTGCCACTGT-3 0 ; 36B4 forward 5 0 -CAT GCTCAACATCTCCCCCTTCTCC-3 0 and reverse 5 0 -GGGA AGGTGTAATCCGTCTCCACA-3 0 .
Biochemistry
Cell lysis, immunoprecipitation, western blotting and in vitro kinase assays for SFK and CSK were preformed as described in Boureux et al. (2005) . Protein expression and phosphorylation were quantified using ImageQuant TL software (GE Healthcare, Saclay, France), and adjusted for background noise and protein loading. For membrane/cytoplasm fractionations, 10 6 cells in a 60 mm plate were lysed in hypotonic buffer (10 mM Tris-Hcl (pH 7.5); 5 mM MgCl 2 ; 1 mM dithiothreitol; and 1 mM phenylmethylsulphonyl fluoride), subjected to Dounce homogenizer with 10 strokes and then centrifuged at 600 g for 5 min to remove nuclei and large cellular debris. Soluble proteins and plasma membrane fractions (pellets) were separated by centrifugation at 100 000 g for 45 min. Lipid raft fractionations were done as described in Veracini et al. (2008) .
Immunostaining Immunostaining was performed as described in Collin et al. (2007) . Briefly, cells were fixed for 10 min with 3.7% paraformaldehyde and permeabilized for 3 min with 0.2% Triton in phosphate-buffered saline. They were next incubated for 1 h with anti-Csk followed by anti-Rabbit-FITC (Sigma Aldrich), anti-phospho-Src (Tyr418) clone 9A6 (Millipore, Molsheim, France) followed by anti-mouse Alexa-594 (Molecular Probes). Confocal images were acquired sequentially on a LSM 510 Meta Zeiss microscope (Zeiss, Le Pecq, France), equipped with a Â 63 Apo W 1.2 N/A objective, using Ar 488-nm and He/Ne 543-nm excitation lasers. Fluorescein isothiocyanate and Alexa-594 channels were acquired using BP 505/ 530 and LP 560 emission filters, respectively. Image processing and analysis were performed on Image J software (opensource, http://rsb.info.nih.gov/ij/).
